Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic User Fees Need Small Business Waiver, Firms Say; Congress May Agree

Executive Summary

Small business owners say the GDUFA facility and other fees are too expensive, especially while waiting for ANDAs to be approved, but any small business waiver is unlikely until GDUFA II.

You may also be interested in...



FDA Reports Millions In Unpaid GDUFA Fees

The $20m in generic drug user fee receivables was 12% of the estimated total to be collected in 2018.

US FDA Reports Millions In Unpaid GDUFA Program Fees

The $20m in generic drug user fee receivables was 12% of the estimated total to be collected in 2018.

ANDA Modifications: US FDA Wants More Formal Facility-Initiated Withdrawals

Facilities that cannot coax an ANDA sponsor to amend their application to exclude a center will have to convince a "less comfortable" FDA with a larger record.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS055428

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel